Several studies have demonstrated the potential protective effects of TTh in men with a history of prostate cancer. In medicine, Nobel Prize winner Charles Huggins wrote in 1941 that testosterone "activates" prostate cancer, and this belief persists to the present day despite overwhelming evidence to the contrary,11 as reviewed hereunder. In one study, men with advanced prostate cancer and symptomatic from TD were so desirous of TTh that they were willing to undergo treatment despite being told TTh was likely to cause rapid progression and death (22 pts), and were so pleased with their result that they remained on treatment for a median of 12 months.10 In the pages that follow are summaries of evidence showing that TTh has important beneficial effects on several of the most common and costly medical conditions, including metabolic disease and obesity, T2DM, and CV disease.
These observations indicate that testosterone administration improves body weight and metabolic factors in men with hypogonadism, but withdrawal of testosterone reverses these beneficial effects, which reappear when TRT is resumed. Our observation indicates that testosterone administration improves body weight and metabolic factors in men with hypogonadism, but withdrawal of testosterone reverses these beneficial effects, which appear again when TTh is resumed 9,10. One study discussed the cut-off value, four studies discussed the effect of TRT on control of T2DM, four studies on duration and interruption of TRT, and 20 studies discussed effect of TRT on the prostate. For TTh, gels and long-acting TU 1000 mg can both help to bring the testosterone level to a steady state physiological concentration, with the long-acting IM injections (TU 1000 mg for quarterly IM injections, available since November 2004) reaching higher physiological levels, which results in more profound clinical effects and preferable benefits on different organ systems. To review the latest innovations and advances in testosterone treatments including their advantages and disadvantages and to address important issues in testosterone therapy (TTh). Such analyses cannot reliably be done in a trial-level meta-analysis such as this one and will require individual patient data meta-analysis (ie, data on every participant). For example, the outcome of bone health was only reported in three RCTs that were not designed to study bone health.
However, it is essential to note that further research is warranted due to the limited number of RCTs available for this specific analysis. Additionally, it should be emphasized that some participants in the study did not suffer from ED. However, there was no research diagnosed ED and assessed the efficacy of TRT by an objective evaluation method such as a nocturnal penile tumescence and rigidity analysis. This improvement was noteworthy, especially since intramuscular and oral doses were each utilized in only one study. The result declared that the differences in PSA levels were similar in two groups regardless of year of publication (Supplementary Figure 6). The results stated that the changes in PSA were similar after treatment in both groups regardless of mode of administration (Figure 9A). The meta-analyses revealed that the improvements in the PVR were similar between the two groups (Figure 8).
These advantages include better vascular function, mood, muscle strength, bone density, and sexual health in healthy men. Testosterone supplements can have a good impact on a number of important aspects of men's health, such as vascular endothelial function, mood (particularly in lowering depression), muscle strength, bone health, and sexual function. Descriptive, observational, and experimental studies including healthy men-more especially, those assessing the effects of testosterone therapy-were required for inclusion. Research indicates that testosterone therapy may improve vaginal lubrication and overall sexual satisfaction in women with low testosterone levels . These benefits include improvements in sexual function, bone health, muscle strength, mood, and vascular endothelial function in healthy individuals. We think our findings offer some reassurance to doctors and patients that testosterone replacement therapy does not increase the risk of heart problems.
The PSA levels were normal for all patients at baseline, and no patient underwent a prostate biopsy at the start of the study. The strongest evidence supports improved sexual desire and related sexual-function outcomes in postmenopausal women with HSDD. Oral testosterone is generally not recommended because of unfavorable lipid effects, and long-term safety data remain more limited than many patients realize. But current consensus documents say the evidence is insufficient to recommend testosterone therapy for cognition, general wellbeing, depressed mood, musculoskeletal health, or disease prevention. The benefits of trt for women may include better sexual desire and related sexual-function measures in selected postmenopausal women. If the question is where testosterone therapy may actually help women, the clearest answer is sexual desire in appropriately selected postmenopausal women with HSDD.
Indirectness (use of surrogate outcomes) affected lipids and bone density outcomes. In addition, several measures that protect from bias were undertaken to ensure high quality of article selection and data extraction. The strength of this systematic review stems from the fact that it was protocol-driven, done in a systematic manner, involved a comprehensive search of several databases, and was performed in collaboration with content experts.
These lines of evidence argue strongly for the need for greater awareness in the medical community of the impact of TD on health, and of the health benefits of TTh. Normalization of physiological T reduces myocardial infarction, stroke, and deaths compared with men whose testosterone levels failed to normalize. By identifying limitations in existing studies and suggesting directions for future investigations, we hope to encourage the research community to pursue more robust and methodologically sound studies that will further strengthen the evidence base. Furthermore, via binding to androgen receptors in muscle cells, testosterone stimulates protein synthesis and muscular growth, which is crucial for the regulation of muscle mass . Based on the predetermined criteria, publications that evaluated the effects of testosterone using descriptive, observational, or experimental designs involving human subjects were included. Because it promotes protein synthesis and muscle hypertrophy through androgen receptor binding in muscle cells, testosterone is a critical regulator of muscle mass; this anabolic impact is required for muscle development and repair, making testosterone crucial for preserving muscle mass . Essential for bone maturation, testosterone helps bones reach maximal mass and preserves bone density, all during adulthood; it also promotes skeletal growth by improving mechanical loading .
One-fifth of the studies reported treatment adherence assessment, and only 25% analyzed participants as randomized (intention-to-treat analysis). We included randomized controlled trials (RCTs) that enrolled postmenopausal women with normal adrenal function who were assigned to T therapy with or without estrogen and compared to either estrogens alone or placebo. Subsequently, the task force requested a systematic review and meta-analysis summarizing the best available evidence on this topic. Testosterone in women exerts its effect through androgen receptors located in several organs of the body, including breast, brain, ovaries, bone, muscle, fat, liver, and skin (1, 2). In this meta-analysis of RCTs, TRT could improve the erectile function of hypogonadal men.